New Research Platform Advances Study of Mitochondrial Diseases
全新研究平台推動粒線體疾病研究進展
On April 10, 2026, scientists at the Salk Institute announced a groundbreaking advancement in mitochondrial research.
2026年4月10日，索爾克研究所的科學家宣布在線粒體研究上取得了突破性進展。
Historically, mitochondrial diseases have been notoriously difficult to study due to their complexity and the phenomenon of "heteroplasmy," where healthy and mutated DNA coexist within cells.
從歷史上看，線粒體疾病因其複雜性以及「異質性」(ㄧˋㄓˋㄒㄧㄥˋ)（即健康與突變的DNA在細胞內共存的現象）而極難研究。
To address this, researchers developed a new platform featuring a library of 155 mitochondrial DNA (mtDNA) mutant cell lines.
為了解決這個問題，研究人員開發了一個包含155個線粒體DNA (mtDNA) 突變細胞系的庫。
By utilizing a specific protein to trigger random mutations, the team created a scalable resource that mimics human disease diversity.
該團隊利用一種特定的蛋白質觸發隨機突變，創造出一個能夠模擬人類疾病多樣性的可擴展資源。
This breakthrough allows researchers to model how specific mutations lead to clinical symptoms, shifting the field from observational study to precision disease modeling.
這一突破使研究人員能夠模擬特定突變如何導致臨床症狀，將該領域從觀察性研究轉向精準疾病建模。
The implications are far-reaching; the platform aims to accelerate the development of targeted therapies not only for rare primary mitochondrial disorders but also for age-related conditions and cancer.
其影響深遠；該平台旨在加速針對罕見原發性線粒體疾病，以及與年齡相關的病症和癌症的標靶治療藥物的開發。
As global research landscapes evolve, integrating these stem-cell-based models with new imaging techniques and data-sharing infrastructures will be vital.
隨著全球研究環境的演變，將這些基於幹細胞的模型與新成像技術及數據共享基礎設施相結合至關重要。
Ultimately, the Salk Institute’s innovation provides a critical bridge between fundamental laboratory discoveries and the development of effective, life-changing human clinical treatments.
最終，索爾克研究所的這項創新為基礎實驗室發現與開發有效的、改變生命的臨床治療方法之間搭建了一座關鍵的橋樑。
